Compare NATH & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATH | TRDA |
|---|---|---|
| Founded | 1916 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.8M | 481.6M |
| IPO Year | 1996 | 2021 |
| Metric | NATH | TRDA |
|---|---|---|
| Price | $100.59 | $13.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 40.3K | ★ 191.9K |
| Earning Date | 05-22-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 22.29 | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $104,201,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $53.29 |
| P/E Ratio | $24.10 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.00 | $4.93 |
| 52 Week High | $118.32 | $13.30 |
| Indicator | NATH | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 63.49 |
| Support Level | $100.25 | $9.59 |
| Resistance Level | $101.86 | N/A |
| Average True Range (ATR) | 0.47 | 0.85 |
| MACD | -0.20 | 0.12 |
| Stochastic Oscillator | 39.97 | 94.49 |
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.